<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689569</url>
  </required_header>
  <id_info>
    <org_study_id>Prebiotic study</org_study_id>
    <nct_id>NCT03689569</nct_id>
  </id_info>
  <brief_title>Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function and Cognition in CKD</brief_title>
  <official_title>Effects of Prebiotic Supplementation and Exercise on Inflammatory Markers, Vascular Function, Cognition, and Mental Well-being in Pre-Dialysis Kidney Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Springfield College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Springfield College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is primarily designed to examine the effect of 16 weeks of prebiotic
      supplementation (resistant starch)and moderate intensity aerobic training on markers of
      inflammation in stage 3-4 patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the proposed study is to determine whether the consumption of a prebiotic
      supplement (resistant starch) coupled with moderate intensity endurance training over 16
      weeks leads to reductions in key inflammatory markers in stage 3-4 predialysis CKD patients
      and whether this reduction is associated with favorable changes in vascular function and
      indicators of stress and emotional reactivity.

      The investigators hypothesize that supplementation with the prebiotic (resistant starch) will
      lead to normalization of the microbiome of our sample of patients with chronic kidney disease
      (CKD) and reduce key markers of inflammation. Reductions in these biomarkers will be
      associated with favorable changes in cardiovascular variables along with indices of stress
      and emotional reactivity. Moderate intensity aerobic training will have an additive
      anti-inflammatory effect along with the consumption of the resistant starch.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An Intention-To-Treat design will be used in this study. Effects of treatment on all dependent variables will be assessed by a 2 (prebiotic supplement or control) by 2 (aerobic exercise or control) by 3 (time) mixed factor ANOVA</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double blind study. Neither the participant nor the investigator will know what substance (resistant starch or corn starch) the participants will be consuming.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hs CRP</measure>
    <time_frame>baseline and after 16 weeks</time_frame>
    <description>hsCRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TNF alpha</measure>
    <time_frame>Baseline and at week 16</time_frame>
    <description>TNFalpha</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL6</measure>
    <time_frame>Baseline and at week 16</time_frame>
    <description>IL6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IL10</measure>
    <time_frame>Baseline and at week 16</time_frame>
    <description>IL10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MCP1</measure>
    <time_frame>Baseline and at week 16</time_frame>
    <description>MCP1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vascular function</measure>
    <time_frame>Baseline, week 8 and week 16</time_frame>
    <description>Pulse wave velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiome composition</measure>
    <time_frame>Baseline and after 16 weeks</time_frame>
    <description>The composition of the microbiome will be assessed at baseline and after 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline &amp; after 16 weeks</time_frame>
    <description>central blood pressure</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resistant Starch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise &amp; Resistant Starch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exercise &amp; resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resistant starch</intervention_name>
    <description>Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion</description>
    <arm_group_label>Exercise &amp; Resistant Starch</arm_group_label>
    <arm_group_label>Resistant Starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity</description>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_label>Exercise &amp; Resistant Starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Starch</intervention_name>
    <description>Patients will be given 30 grams of corn starch</description>
    <arm_group_label>Starch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage 3-4 of CKD (GFR 15-59 ml/min/1.73m2),

          -  ages of 30-75 years old,

          -  Must be capable of complying with and following the study protocol(diet and exercise)

          -  Must be capable of independently giving informed consent

        Exclusion Criteria:

          -  kidney transplant

          -  currently in a structured exercise program

          -  on antibiotic therapy within the last month

          -  On a probiotic or prebiotic supplement within the last month

          -  a GI disorder that prohibits the use of resistant starch (ie. high-amylose corn
             starch, which resists digestion

          -  HIV positive

          -  gastric by-pass surgery

          -  clostridium difficile

          -  marijuana user

          -  lupus

          -  rheumatoid arthritis

          -  Hepatitis C

          -  Post-traumatic stress disorder

          -  deep vein thrombosis

          -  pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel A Headley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Springfield College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel A Headley, PhD</last_name>
    <phone>413-748-3340</phone>
    <email>sheadley@springfieldcollege.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Harnsberger, PhD</last_name>
    <phone>413-748-4826</phone>
    <email>jharnsberger@springfieldcollege.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Springfield College</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel A Headley, Ph.D</last_name>
      <phone>413-748-3340</phone>
      <phone_ext>3340</phone_ext>
      <email>sheadley@springfieldcollege.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel A Headley, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Germain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Springfield College</investigator_affiliation>
    <investigator_full_name>Samuel A. Headley</investigator_full_name>
    <investigator_title>Professor Exercise Science &amp; Sport Studies</investigator_title>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>inflammation</keyword>
  <keyword>resistant starch</keyword>
  <keyword>exercise training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

